Japanese Services Provider AGREX Expands Global Medidata Rave Services Through ASPire to Win Accreditation

Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical technology solutions, today announced that AGREX, a Japan-based business process outsourcing organization has reached Rave Accredited Plus, the most advanced level in Medidata’s ASPire to Win^® channel partner program for contract research organizations (CROs) and other service providers. With this accreditation, AGREX can now offer full implementation services and support around the Medidata Rave^® electronic data capture (EDC) and clinical data management (CDM) solution.

Headquartered in Tokyo, AGREX provides a broad range of business process outsourcing services, including clinical development services and professional IT support to help sponsors improve the speed, quality and efficiency of clinical studies. Impressed with Medidata’s operational results among its global customer base, AGREX viewed the ASPire to Win Rave Accredited Plus milestone as critical to its future growth. With AGREX’s Rave-trained data management teams in Tokyo and Osaka, AGREX customers will benefit from Medidata Rave’s ability to efficiently capture data on a large scale and work with the system in the language of their choice. Moreover, the partnership has enabled AGREX to complement its deep data management expertise with a full range of Rave services, allowing the CRO to expand its reach, broaden its business opportunities and increase ROI to supports its growing CRO division.

"This accreditation allows us to respond to increasing sponsor demand for a full set of services around Medidata Rave,” said Mototsugu Suzuki, Director, Senior Managing Executive Office, AGREX. "Medidata Rave continues to be a preferred solution in executing global studies and achieving the highest level of accreditation with the ASPire to Win program will bring new opportunities to expand our customer base.”

As a Rave Accredited Plus partner, AGREX can provide its customers with a full suite of Medidata Rave-related services including end-user training, study build, reporting, outputs, integrations and migrations. As a result, AGREX can further enable clients to leverage Medidata Rave to improve the quality and the efficiency of global studies and provide sites with a user-friendly system.

"We are very pleased to welcome AGREX as a Medidata channel partner to help us serve our growing customer base in Japan and across Asia,” said Graham Bunn, Vice President for Global CRO Partnerships, Medidata Solutions. "As a leading Japanese services provider, AGREX will provide critical services to support clinical research activity and deliver the benefits of Medidata Rave on a global scale.”

Medidata first announced ASPire to Win in April 2005 as a channel partner program designed to enable select CROs and other service providers to offer Medidata Rave implementation services. Since then, ASPire to Win has grown to include 25 partners, ranging from smaller clinical consultancies to large, global CROs.

About AGREX

AGREX serves the financial and other industries as a leading BPO (Business Process Outsourcing) service company in Japan. In 2002, AGREX began providing CRO (Clinical Research Organization) services based on decades of BPO experience. AGREX's CRO services are very progressive, powered by both information technology and pharmaceutical knowledge and with a focus on globalization. To learn more, please visit www.agrex.co.jp.

About Medidata Solutions Worldwide

Medidata Solutions (www.mdsol.com) is a leading global provider of SaaS-based clinical technology solutions that enhance the efficiency of customers’ clinical development processes and optimize their research and development investments. Medidata products and services allow customers to achieve clinical results more efficiently and effectively by streamlining the design, planning and management of key aspects of the clinical development process, including protocol development (Medidata Designer^®), investigator benchmarking and budgeting (Medidata Grants Manager^®), contract research organization (CRO) benchmarking and budgeting (Medidata CRO Contractor^®), and the capture, management, analysis and reporting of clinical trial data (Medidata Rave^®). Medidata’s diverse customer base spans pharmaceutical, biotechnology and medical device companies, academic institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies.